Description
Tenatoprazole is a proton pump inhibitor, blocking hog gastric H
+/K
+-ATPase activity with an IC
50 value of 6.2 μM. It is orally bioavailable, blocking induced gastric acid secretion and ulcer formation in rats and humans. Tenatoprazole has a prolonged plasma half-life resulting in persistent effectiveness after withdrawal.
Definition
ChEBI: 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methylsulfinyl]-1H-imidazo[4,5-b]pyridine is an imidazopyridine.
References
[1] K UCHIYAMA. Effects of TU-199, a novel H+, K(+)-ATPase inhibitor, on gastric acid secretion and gastroduodenal ulcers in rats.[J]. Methods and findings in experimental and clinical pharmacology, 1999, 21 2: 115-122. DOI:
10.1358/mf.1999.21.2.529238[2] J. P. GALMICHE. Tenatoprazole, a novel proton pump inhibitor with a prolonged plasma half-life: effects on intragastric pH and comparison with esomeprazole in healthy volunteers[J]. Alimentary Pharmacology & Therapeutics, 2004, 19 6: 655-662. DOI:
10.1111/j.1365-2036.2004.01893.x[3] RICHARD H HUNT. Effect on intragastric pH of a PPI with a prolonged plasma half-life: comparison between tenatoprazole and esomeprazole on the duration of acid suppression in healthy male volunteers.[J]. American Journal of Gastroenterology, 2005, 100 9: 1949-1956. DOI:
10.1111/j.1572-0241.2005.41956.x
